(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today - 2Americans generally like wolves − except when we’re reminded of our politics
- 3Blood pressure drug recalled for possible cross-contamination
- 4Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- 5The Significance of a Land Lawyer for Your Business
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Nations for Rock Climbing
- How to watch 'A Charlie Brown Christmas' for free in 2025
- 74 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
- What you need to know about flu treatments as cases spike across the US
- Russia patents space station designed to generate artificial gravity
- Coca-Cola Co. and bottlers to invest in South Africa operations
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Israel says it will keep control over part of southern Lebanon after war with Hezbollah ends
